• SciSparc posted a net loss of USD 6.05 million for the six months ended June 30, 2026, narrowing from USD 9.41 million.
• Revenue fell 38% to USD 284,000, while operating loss widened to USD 4.89 million from USD 2.71 million.
• Research and development expenses climbed 68% to USD 1.58 million, and general and administrative expenses rose 52% to USD 3.2 million.
• Cash and cash equivalents totaled USD 4.44 million at June 30, 2026, up from USD 1.55 million at June 30, 2025.
• NeuroThera acquired 54.01% of CliniQuantum on June 3, 2026, adding USD 10.32 million of intangible assets and a USD 1.99 million earn-out liability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scisparc Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-105319), on September 30, 2026, and is solely responsible for the information contained therein.